RLYB Rallybio Corporation
Healthcare$14.70-7.43%ClosedMarket Cap: $77.9M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.80
P/S
98.06
EV/EBITDA
-1.53
DCF Value
$10.84
FCF Yield
-32.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.7%
Operating Margin
-3278.2%
Net Margin
-911.1%
ROE
-14.4%
ROA
-14.4%
ROIC
-55.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $212.0K | 98.6% | $-4.7M | $-8.3M | $— | — |
| Q4 null | $222.0K | 100.0% | $-6.4M | $-5.9M | $— | — |
| FY null | $858.0K | 89.3% | $-28.1M | $-9.0M | $— | — |
| Q3 null | $212.0K | 100.0% | $-6.9M | $16.0M | $— | — |
| Q2 null | $212.0K | 100.0% | $-10.1M | $-9.7M | $— | — |
| Q1 null | $212.0K | 100.0% | $-9.7M | $-9.4M | $— | — |
| Q4 null | $38.0K | 21.1% | $-11.6M | $-11.0M | $— | — |
| FY null | $636.0K | 100.0% | $-60.5M | $-57.8M | $— | — |
| Q3 null | $299.0K | 100.0% | $-12.1M | $-11.5M | $— | — |
| Q2 null | $299.0K | 88.6% | $-17.0M | $-16.2M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-19.8M | $-19.0M | $— | — |
| Q4 2023 | $228.0K | 50.0% | $-21.1M | $-20.2M | $-4.00 | — |